Evidence map›Paper›PMID 42827226›Full record

ArticleInternational journal of hematology2026

Potential clinical benefits of early belumosudil treatment in chronic graft-versus-host disease.

Akihisa Hino, Tomoaki Ueda, Shinsuke Kusakabe, Hidenori Kasahara, Keigo Akuta, Hiroyuki Takamori, Jiro Fujita, Naoki Hosen, Kentaro Fukushima

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Akihisa HinoDepartment of Haematology and Oncology, The University of Osaka Graduate School of Medicine, Suita, 565-0871, Japan.ORCID http://orcid.org/0000-0002-7331-2713
Tomoaki UedaDepartment of Haematology and Oncology, The University of Osaka Graduate School of Medicine, Suita, 565-0871, Japan.
Shinsuke KusakabeDepartment of Haematology and Oncology, The University of Osaka Graduate School of Medicine, Suita, 565-0871, Japan.
Hidenori KasaharaDepartment of Haematology and Oncology, The University of Osaka Graduate School of Medicine, Suita, 565-0871, Japan.
Keigo AkutaDepartment of Haematology and Oncology, The University of Osaka Graduate School of Medicine, Suita, 565-0871, Japan.
Hiroyuki TakamoriDepartment of Haematology and Oncology, The University of Osaka Graduate School of Medicine, Suita, 565-0871, Japan.
Jiro FujitaDepartment of Haematology and Oncology, The University of Osaka Graduate School of Medicine, Suita, 565-0871, Japan.
Naoki HosenDepartment of Haematology and Oncology, The University of Osaka Graduate School of Medicine, Suita, 565-0871, Japan.
Kentaro FukushimaDepartment of Haematology and Oncology, The University of Osaka Graduate School of Medicine, Suita, 565-0871, Japan. kfukushi@bldon.med.osaka-u.ac.jp.ORCID http://orcid.org/0000-0002-8003-2584

Funding

JSPS KAKENHI 25K19575
6 · The paper itself

Abstract

objectivesAdministering belumosudil before chronic graft-versus-host disease (cGVHD) fibrosis progresses may improve response rates. Nonetheless, clear evidence is lacking regarding the effects of treatment timing or history on response to belumosudil. We examined the effects of early belumosudil treatment in cGVHD. STUDY

designThis retrospective cohort study identified 23 patients who received belumosudil for cGVHD at The University of Osaka Hospital from May 2024 to January 2026. The median time from cGVHD onset to belumosudil initiation was 228 days. Fourteen patients received belumosudil early, within 1 year of cGVHD onset, and fourteen received it as second-line therapy.

resultsAt the patient level, the overall response rate was 85.7% in the early-treatment group and 50.0% in the late-treatment group, but the difference was not statistically significant (p = 0.137). In the exploratory organ-level analysis, early treatment was associated with significant improvement in cGVHD scores compared with late treatment. No significant differences in response were observed between second-line and later-line therapy.

conclusionsAlthough these findings are at the organ level, this study suggests that, regardless of prior treatment, early administration of belumosudil following the onset of cGVHD may be associated with improved response.

Indexed as

Allogeneic hematopoietic stem cell transplantationChronic GVHD

Identifiers

PMID42827226

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.